Alx Oncology Holdings Inc
ALXO
Market Cap$24.59M
Close$
$0.15
68.1% downside
Current Fair Value
68.1% downsideOvervalued by 68.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $24.59 Million |
|---|---|
| Enterprise Value | $9.65 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.58 |
| Beta | 1.16 |
| Outstanding Shares | 53,359,338 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | 1.39 |
| Price to Sales | - |
| Price to Book Ratio | 0.46 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.59 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Alx Oncology Holdings Inc
23 employeesALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.